More Than Mirrors: Gentex, Vital Farms, and the Art of Hands-On Research

Taking the Market's Temperature

MIPAR sits at 7.6% as we close out February 2026. That puts the Sweet Spot for stock shopping between 12.6% and 17.6%. Not exactly a fire sale, but not nose-bleed territory either.

We think all investors should notice what happens in this kind of environment. The bargains aren't obvious. They require some digging. And our community has been doing exactly that.

Gentex (GNTX): More Than Mirrors

You'll find Gentex in any number of community portfolios, from Tin Cup to Buttonwood to a multi-time selection for the Round Table. The quality ranking has been flat-lining near 100. The balance sheet is fortress-like, with virtually no debt and sitting on cash.

But here's where it gets interesting.

We encourage an appropriate balance of focus on the rear view mirror while using your brights for the windshield. And through the windshield, Gentex has a patent portfolio that most investors overlook entirely: 2,313 patents (815 US, 1,489 foreign) plus 549 pending applications.

Beyond the auto-dimming mirror business, Gentex has developed eSight Go electronic eyewear for the legally blind ($5,000 to $10,000, available through the VA), RetiSpec technology for early Alzheimer's detection, and a Mayo Clinic agreement for germ-killing surgical lighting.

The community has been debating a genuine question: is management too focused on the auto industry to fully exploit these innovations? It's the kind of question that separates a good stock from a great one. And it's the kind of question that only surfaces when a community of investors digs in together.

Vital Farms (VITL): The Misunderstood Egg Company

Short interest sits at roughly 28% of float. That's unusual for a profitable, fast-growing company. CEO Russell Diez-Canseco put it well at the Morgan Stanley conference: "The thing that we have that's a scarce commodity isn't an egg, it's a trusted brand."

A key distinction that most investors miss: specialty pasture-raised eggs are sold on long-term contracts, not the commodity spot market. VITL's performance is not tied to commodity egg price swings. We can't help but notice that this structural insight changes an entire investment thesis.

The growth story is concrete. The company is targeting $2 billion in revenue by 2030, with a second facility (Vital Crossroads, in Seymour, Indiana) adding $900 million in capacity by 2027. Matt S. has been doing outstanding work tracking the capacity curve, the investor day details, and the analyst coverage on this one. The community discussion has been exceptional.

Peter Lynch at the Grocery Store

Speaking of community research: Keith A. was recently in Walmart and decided to check if they carry Vital Farms eggs. $7.49 a dozen. The manager looked at her computer and told him they sold 81 dozen last week.

Sometimes the best research starts in aisle 7.

Peter Lynch built a legendary track record partly on this principle. You don't need a Bloomberg terminal to notice which products are flying off shelves, which stores are packed, or which brands your neighbors keep buying. Victoria V. sampled the product at Publix ($9.99 a dozen). Marie F. compared prices at Tom Thumb. Matt S. pulled the Investor Day slides showing Target's sell-through data and shelf velocity metrics.

One member checks the balance sheet. Another reads the patent filings. Somebody else walks into Walmart and asks the manager about the eggs. Stitch those perspectives together and you raise the probability of success for the whole community.

Keep Digging

If you want to see more of how we approach stock research, our Technology Manager, Kurt Kowitz, recently walked through our stock search alerts, data aggregation from Value Line, S&P, and Morningstar, and our AI-powered video processing system at a recent Discovery webinar. Watch the recording here.

The tools keep getting better. But the real edge is the community of investors willing to do the work.